<DOC>
	<DOCNO>NCT01267162</DOCNO>
	<brief_summary>This Phase IV , open-label , single-arm , 96 week community-based observational study evaluate antiviral efficacy , safety , tolerability TDF HBV mono-infected Asian-American adult complete 48 week treatment Tenofovir Gilead 174-0123 study . The primary objective study evaluate long-term antiviral efficacy tenofovir DF 300 mg daily patient . The secondary objective evaluate safety tolerability TDF include biochemical virological response TDF , incidence drug resistance mutation patient The duration treatment study total three Years ( 144 week ) TDF .</brief_summary>
	<brief_title>Long-term Study Anti-HBV Effect Tenofovir Resistance Surveillance Asian-American Adult Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Male female , AsianAmerican , participate complete study , qualify follow criterion , remain TDF treatment without severe treatmentrelated AEs , available retrospective lab result summarize Appendix 2 . 18 75 year age , inclusive Willing participate present study able provide write informed consent Continuation HBV treatment indicate . That HBeAgpositive subject , HBeAg remain positive HBeAg becomes negative still detectable DNA PCR method ; HBeAgnegative subject , HBV DNA either detectable undetectable PCR method No clinical virologic evidence antiHBV resistance TDF treatment time enter test ( i.e. , TDF treatment week 48 lab test 123 study ) Estimated glomerular filtration rate ( creatinine clearance ) ≥ 60 mL/min/1.73m2 CockcroftGault equation : ( 140age year ) ( body weight [ kg ] ) ( 72 ) ( serum creatinine [ mg/dl ] ) [ Note : multiply estimate rate 0. 85 woman ; use actual body weight ] • Adequate hematologic function ( absolute neutrophil count ≥ 1,500/mm3 ; hemoglobin ≥ 10.0 g/dL ) Pregnant woman , woman breast feed believe may wish become pregnant course study . Males females reproductive potential willing use effective method contraception study . For male , condom use female , barrier contraception method use combination one form contraception . Willing able provide write informed consent Decompensated liver disease define direct ( conjugate ) bilirubin ≥ 1.2 ULN ; PT ≥ 1.2 ULN , platelets ≤ 150,000/mm3 , serum albumin ≤ 3.5 g/dL Prior history clinical hepatic decompensation ( e.g. , ascites , jaundice , encephalopathy ) variceal hemorrhage Serum αfetoprotein ≥ 50 ng/mL Evidence hepatocellular carcinoma ( HCC ) Coinfection HIV , HCV , HDV History significant renal disease ( e.g. , nephrotic syndrome , renal dysgenesis , polycystic kidney disease , congenital nephrosis , acute tubular necrosis , renal disease ) History significant bone disease ( e.g. , osteomalacia , chronic osteomyelitis , osteogenesis imperfecta , osteochondroses , multiple bone fracture ) Significant cardiovascular , pulmonary neurological disease Evidence gastrointestinal malabsorption syndrome may interfere absorption orally administer medication History solid organ bone marrow transplantation Ongoing therapy following : Nephrotoxic agent Parenteral aminoglycoside antibiotic ( e.g. , gentamicin , tobramycin , amikacin ) Cidofovir Cisplatin Foscarnet IV amphotericin B IV pentamidine Oral IV ganciclovir Cyclosporine Tacrolimus IV vancomycin Chronic daily nonsteroidal antiinflammatory drug therapy Competitors renal excretion ( e.g. , probenecid ) Systemic chemotherapeutic agent Systemic corticosteroid Interleukin2 ( IL2 ) immunomodulating agent Investigational agent ( except express approval lead investigator ) Administration medication must discontinue least 30 day prior Baseline Visit duration study period . Known hypersensitivity study drug , metabolite formulation excipients Any condition ( include alcohol substance abuse ) prior therapy , opinion Investigators , would make subject unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>CHB</keyword>
</DOC>